FASN and fatty liver disease: Nrf2 activation prevents metabolic dysregulation and insulin resistance in mice through the repression of hepatic enzymes such as FASN and ACC and protects against hypertriglyceridemia and fatty liver disease; this protection is abolished when Nrf2 is deleted [118].